
|Articles|March 15, 2019
Pharmacy Practice in Focus: Health Systems
- March 2019
- Volume 8
- Issue 2
Improving the Performance of Specialty Pharmacists in the Care of Patients With Pulmonary Arterial Hypertension
Advertisement
FACULTY:
James S. Kalus, PharmD, FASHP Director of Pharmacy Henry Ford Health System Detroit, Michigan
EDUCATIONAL OBJECTIVES:
At the completion of this activity, the participant will be able to:
- Analyze the unaddressed gaps of reversal agents for direct oral anticoagulants (DOACs) and the risk of bleeding complications
- Identify patients hwho are at high risk for major bleeding secondary to DOAC use
- Examine current and emerging DOAC reversal agents and their safety and efficacy
- Explore the role of the health-system pharmacist in ensuring optimal management of the patient with DOAC-associated bleeding and implementing standards of practice for reversal agents using clinical vignetttes.
TARGET AUDIENCE: Health-system pharmacists
ACTIVITY TYPE: Application
RELEASE DATE: March 15, 2019
EXPIRATION DATE: March 15, 2020
ESTIMATED TIME TO COMPLETE ACTIVITY: 2.0 hours
FEE: This lesson is offered for free at
Articles in this issue
about 7 years ago
Use AUC to Optimize Vancomycin Dosingabout 7 years ago
Approach Respiratory Illnesses Rationallyabout 7 years ago
Manage Acute Pain in Those Using Opioidsabout 7 years ago
Documenting 340B Value Is Key to Successabout 7 years ago
Panelists Discuss Challenges of Diagnosing HEabout 7 years ago
News and Trends March 2019about 7 years ago
Perform an AOR to Comply With USPabout 7 years ago
Enterprise Collaborations Help Meet Challengesabout 7 years ago
Cancer Pain Treatment Remains a Challengeabout 7 years ago
Here Is What to Know About Vaccines for SeniorsAdvertisement
Latest CME
Advertisement
Advertisement
Trending on Pharmacy Times
1
A Paradigm Shift in Lipid Management: Highlights from the NLA 2026 Scientific Sessions Opening Session
2
ATTR-CM Red Flags, Treatment Evidence, and the Pharmacist's Role in Care
3
Anticoagulation in AFib: Risk Stratification, Therapy Selection, and Factor XI Inhibitors
4
FDA Approves Belzutifan Plus Pembrolizumab for Adjuvant Treatment of High-Risk Clear Cell RCC
5


































































































































